
Figure 2 FDA Recommendations for Quarantine and Disposition of Prior Collections,
Supplemental Testing, and Notification of Consignees and Transfusion Recipients
Based on EIA 2.0 or EIA 3.0 Donor Test Results for Antibody to Hepatitis C Virus (Anti-HCV) (Cont.)



<sup>&</sup>lt;sup>1</sup> Previously distributed prior collections should be identified from the same donor dating back indefinitely to the extent that electronic or other readily retrievable records exist or to the date 12 months prior to the most recent negative multiantigen screening test, whichever is the lesser period.

<sup>&</sup>lt;sup>2</sup> A previously frozen serum or plasma sample from the repeatedly reactive donation.

<sup>&</sup>lt;sup>3</sup> Notify consignees as soon as feasible after obtaining the additional test result.

<sup>&</sup>lt;sup>4</sup> If a licensed RIBA 2.0 test or an investigational RIBA 3.0 test was performed consistent with previous guidance, refer to Figure 1 for outcomes.

<sup>&</sup>lt;sup>5</sup> Transfusion services should identify and notify recipients of prior collections dating back indefinitely.